Savara stock drops after FDA misses review deadline for lung therapy
Savara shares lost 17% to $4.31 after the FDA said it would not meet its November 22 target date for molgramostim, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Savara shares fell 17% to $4.31 in late morning trading on Friday, according to Dow Jones Newswires, and are down 28% so far this year.
The company said the US regulator informed it that the agency will not reach a decision by its target date of Sunday, November 22, on the biologics license application for molgramostim, an inhaled therapy Savara makes for a rare lung disease.
Savara added that the review is still ongoing and that no revised action date has been provided.
why it matters
For investors, the key question is timing: a regulatory delay with no new date keeps the launch of a single-product drug uncertain, which explains the sell-off. The story is company-specific, so its reach beyond small-cap biotech stocks is limited.
tags
instruments
sources
- Savara Shares Tumble, FDA to Miss Target Date for License of Lung Disease Treatment — Dow Jones Newswires, 20 November 2026 at 16:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗